RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Overview of attention for article published in Journal of Clinical Oncology, May 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 8 news outlets
blogs: 1 blog

twitter: 6 X users

Readers on

mendeley: 23 Mendeley

So far, Altmetric has seen 17 news stories from 8 outlets.

RAMP 301 Aims to Solidify Avutometinib Plus Defactinib in Recurrent LGSOC

OncLive, 18 Jun 2024

Jubilee Brown, MD As investigators continue efforts to improve outcomes for patients with low-grade serous ovarian cancer (LGSOC…

Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)

Seeking Alpha, 26 May 2024

Follow Summary Verastem Oncology's stock dropped significantly after the announcement of data from the RAMP-205 study…

Avutometinib Plus Defactinib Signals Changing Tides in Low-Grade Serous Ovarian Cancer

OncLive, 13 May 2024

Jubilee Brown, MD Compounding RAF/MEK inhibition and FAK inhibition through the combination of avutometinib (VS-6766) and…

Avutometinib Receives Orphan Drug Designation for Recurrent Low-Grade Serous Ovarian Cancer

Oncology Nursing News, 16 Mar 2024

An orphan drug designation has been granted by the FDA to avutometinib (VS-6766) alone or in combination with defactinib (VS-6063…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 13 additional news stories.